Skip to main content
Top
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Human Papillomavirus | Research

The prognostic value of LAYN in HPV-related head and neck squamous cell carcinoma and its influence on immune cell infiltration

Authors: Qingjuan Chen, Jiankang Chen, Zuzhuang Lu, Rui Nian, Wanjun Li, Zhongqiang Yao, Shangdong Mou, Ying Liu, Xia Cao, Wenjing He, Chenjing Zhu

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Background

HPV-positive head and neck squamous cell carcinoma (HNSCC) exhibits different characteristics from HPV-negative tumors in terms of tumor development, clinical features, treatment response, and prognosis. Layilin (LAYN), which contains homology with C-type lectins, plays a critical role in tumorigenesis and cancer progression. However, the prognostic value of LAYN and the relationship between LAYN and immune infiltration levels in HPV-related HNSCC patients still require a comprehensive understanding. Herein, we aimed to assess the prognostic value of LAYN and to investigate its underlying immunological function in HPV-related HNSCC.

Methods

Through various bioinformatics methods, we analyzed the data from The Cancer Genome Atlas (TCGA), Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA) databases to explore the potential underlying oncogenic impression of LAYN, including the relevance of LAYN to survival outcomes, clinicopathological factors, immune cell infiltration, and immune marker sets in HPV-related HNSCC. The expression levels of LAYN and HPV were also verified in HNSCC patient tissues.

Results

LAYN was differentially expressed in a variety of tumors. The expression of LAYN in HNSCC was significantly higher than that in adjacent normal tissues (P < 0.0001), and high expression of LAYN was correlated with poor overall survival (OS) in HNSCC patients (Hazard Ratio (HR) = 1.3, P = 0.035). Moreover, LAYN expression level in HPV-positive HNSCC patients was significantly lower than that in HPV-negative patients, with HPV-positive HNSCC patients displaying a trend of favorable prognosis. In addition, the relationship between LAYN expression and immune infiltration levels in HPV-positive HNSCC group was less tightly correlated than that in HPV-negative HNSCC group, and there was a strong relationship between LAYN expression and markers of M2 macrophage (P < 0.001) and exhausted T cells (P < 0.05) in HPV-negative HNSCC. Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis suggested that LAYN potentially influenced tumor progression through HPV infection and other cancer-related pathways.

Conclusions

LAYN might contribute to tumorigenesis via its positive correlation with immune checkpoint molecules and tumor-associated macrophages (TAMs). Our study might provide a novel prognostic biomarker and latent therapeutic target for the treatment of HPV-related HNSCC.
Literature
4.
go back to reference Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–82.PubMedCrossRef Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–82.PubMedCrossRef
5.
6.
go back to reference Ludwig S, et al. mRNA and miRNA profiles of exosomes from cultured tumor cells reveal biomarkers specific for HPV16-positive and HPV16-negative head and neck cancer. Int J Mol Sci. 2020;21(22):8570.PubMedPubMedCentralCrossRef Ludwig S, et al. mRNA and miRNA profiles of exosomes from cultured tumor cells reveal biomarkers specific for HPV16-positive and HPV16-negative head and neck cancer. Int J Mol Sci. 2020;21(22):8570.PubMedPubMedCentralCrossRef
7.
go back to reference Ferris RL, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the checkmate 358 trial. J Immunother Cancer. 2021;9(6):e002568.PubMedPubMedCentralCrossRef Ferris RL, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the checkmate 358 trial. J Immunother Cancer. 2021;9(6):e002568.PubMedPubMedCentralCrossRef
8.
go back to reference Welters MJP, et al. Intratumoral HPV16-specific T cells constitute a type I-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res. 2018;24(3):634–47.PubMedCrossRef Welters MJP, et al. Intratumoral HPV16-specific T cells constitute a type I-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res. 2018;24(3):634–47.PubMedCrossRef
9.
go back to reference Borowsky ML, Hynes RO. Layilin, a novel talin-binding transmembrane protein homologous with C-type lectins, is localized in membrane ruffles. J Cell Biol. 1998;143(2):429–42.PubMedPubMedCentralCrossRef Borowsky ML, Hynes RO. Layilin, a novel talin-binding transmembrane protein homologous with C-type lectins, is localized in membrane ruffles. J Cell Biol. 1998;143(2):429–42.PubMedPubMedCentralCrossRef
11.
go back to reference Weng L, et al. Molecular cloning and characterization of human chondrolectin, a novel type I transmembrane protein homologous to C-type lectins. Genomics. 2002;80(1):62–70.PubMedCrossRef Weng L, et al. Molecular cloning and characterization of human chondrolectin, a novel type I transmembrane protein homologous to C-type lectins. Genomics. 2002;80(1):62–70.PubMedCrossRef
12.
go back to reference Adachi T, et al. Roles of layilin in TNF-alpha-induced epithelial-mesenchymal transformation of renal tubular epithelial cells. Biochem Biophys Res Commun. 2015;467(1):63–9.PubMedCrossRef Adachi T, et al. Roles of layilin in TNF-alpha-induced epithelial-mesenchymal transformation of renal tubular epithelial cells. Biochem Biophys Res Commun. 2015;467(1):63–9.PubMedCrossRef
13.
go back to reference Zheng C, et al. Landscape of infiltrating t cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–56.PubMedCrossRef Zheng C, et al. Landscape of infiltrating t cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–56.PubMedCrossRef
14.
15.
go back to reference De Simone M, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating t regulatory cells. Immunity. 2016;45(5):1135–47.PubMedPubMedCentralCrossRef De Simone M, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating t regulatory cells. Immunity. 2016;45(5):1135–47.PubMedPubMedCentralCrossRef
18.
20.
go back to reference Yang Y, et al. Targeting LAYN inhibits colorectal cancer metastasis and tumor-associated macrophage infiltration induced by hyaluronan oligosaccharides. Matrix Biol. 2023;117:15–30.PubMedCrossRef Yang Y, et al. Targeting LAYN inhibits colorectal cancer metastasis and tumor-associated macrophage infiltration induced by hyaluronan oligosaccharides. Matrix Biol. 2023;117:15–30.PubMedCrossRef
21.
go back to reference Cao L, Zhu L, Cheng L. ncRNA-Regulated LAYN serves as a prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma: a bioinformatics analysis. Biomed Res Int. 2022;2022:5357114.PubMedPubMedCentralCrossRef Cao L, Zhu L, Cheng L. ncRNA-Regulated LAYN serves as a prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma: a bioinformatics analysis. Biomed Res Int. 2022;2022:5357114.PubMedPubMedCentralCrossRef
22.
go back to reference Tanaka A, Sakaguchi S. Targeting treg cells in cancer immunotherapy. Eur J Immunol. 2019;49(8):1140–6.PubMedCrossRef Tanaka A, Sakaguchi S. Targeting treg cells in cancer immunotherapy. Eur J Immunol. 2019;49(8):1140–6.PubMedCrossRef
24.
go back to reference Yu YR, Ho PC. Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting. Clin Exp Immunol. 2019;197(2):153–60.PubMedCrossRef Yu YR, Ho PC. Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting. Clin Exp Immunol. 2019;197(2):153–60.PubMedCrossRef
25.
go back to reference Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.PubMedPubMedCentralCrossRef Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.PubMedPubMedCentralCrossRef
27.
go back to reference Gavrielatou N, et al. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84: 101977.PubMedCrossRef Gavrielatou N, et al. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84: 101977.PubMedCrossRef
28.
go back to reference Bengsch B, et al. Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. Immunity. 2018;48(5):1029–45.PubMedPubMedCentralCrossRef Bengsch B, et al. Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. Immunity. 2018;48(5):1029–45.PubMedPubMedCentralCrossRef
29.
go back to reference McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95.PubMedCrossRef McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95.PubMedCrossRef
30.
go back to reference Chow A, et al. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775–90.PubMedCrossRef Chow A, et al. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775–90.PubMedCrossRef
31.
go back to reference Yang B, et al. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8(+)T cells. Cell Oncol (Dordr). 2022;45(6):1297–309.PubMedCrossRef Yang B, et al. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8(+)T cells. Cell Oncol (Dordr). 2022;45(6):1297–309.PubMedCrossRef
32.
go back to reference Doroshow DB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–62.PubMedCrossRef Doroshow DB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–62.PubMedCrossRef
33.
go back to reference Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.PubMedCrossRef Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.PubMedCrossRef
36.
go back to reference Gunassekaran GR, et al. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278: 121137.PubMedCrossRef Gunassekaran GR, et al. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278: 121137.PubMedCrossRef
37.
go back to reference Han S, et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics. 2021;11(6):2892–916.PubMedPubMedCentralCrossRef Han S, et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics. 2021;11(6):2892–916.PubMedPubMedCentralCrossRef
38.
go back to reference Lechien JR, et al. HPV involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas. Cancers. 2020;12(5):1060.PubMedPubMedCentralCrossRef Lechien JR, et al. HPV involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas. Cancers. 2020;12(5):1060.PubMedPubMedCentralCrossRef
39.
go back to reference Zhu X, et al. Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. J Immunother Cancer. 2022;10(9):e004219.PubMedPubMedCentralCrossRef Zhu X, et al. Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. J Immunother Cancer. 2022;10(9):e004219.PubMedPubMedCentralCrossRef
40.
Metadata
Title
The prognostic value of LAYN in HPV-related head and neck squamous cell carcinoma and its influence on immune cell infiltration
Authors
Qingjuan Chen
Jiankang Chen
Zuzhuang Lu
Rui Nian
Wanjun Li
Zhongqiang Yao
Shangdong Mou
Ying Liu
Xia Cao
Wenjing He
Chenjing Zhu
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00913-5

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine